Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

NCT04373317
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Conditions
Obsessive-Compulsive Disorder
Interventions
Active DBS, Sham DBS
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
9
States / cities
Redwood City, California • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
Conditions
Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
Interventions
Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Therapeutic Conventional Surgery
Dietary Supplement · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Burlington, Massachusetts • Minneapolis, Minnesota + 3 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

An Innovative Intervention for OUD Treatment

NCT04325659
Conditions
Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
Interventions
Bridge Device, Lofexidine, Placebo, Sham Bridge Device
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Knee Osteoarthritis
Interventions
Hylan G-F 20, Control
Device · Other
Lead sponsor
OhioHealth
Other
Eligibility
40 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Geographic Atrophy
Interventions
JNJ-81201887, Prednisone, Placebo, Triamcinolone, Sham Procedure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 66 more
Conditions
Vaginal Dysbiosis
Interventions
FB-301, Placebo, Chlorhexidine (0.5%) Vaginal Cleanse, Sham vaginal cleanse (saline)
Drug · Other
Lead sponsor
Freya Biosciences ApS
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Wichita, Kansas • Waltham, Massachusetts • Charlotte, North Carolina + 1 more
Conditions
Psoriasis
Interventions
Acitretin 25Mg Oral Capsule, Excimer laser, Tazarotene 0.1% Gel,Top, Sham excimer laser
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Not applicable Interventional Accepts healthy volunteers Results available

Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters

NCT01028014
Conditions
Urethral Sphincter Activity
Interventions
Pseudoephedrine, Tamsulosin, Imipramine, Cyclobenzaprine, Lactose capsule, Solifenacin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 51 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Durvalumab, Nintedanib, Placebo, Quality-of-Life Assessment
Biological · Drug · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Neurosciences, Substance-Related Disorders, Behavior Problem
Interventions
Placebo TMS Sham, Marinol 10Mg Capsule TMS Sham, Marinol 30Mg Capsule TMS Sham, Placebo TMS Real, Marinol 10Mg Capsule TMS Real, Marinol 30Mg Capsule TMS Real
Device · Drug · Other
Lead sponsor
Michael J. Wesley, PhD
Other
Eligibility
18 Years to 34 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers

NCT02736799
Conditions
Gastroparesis
Interventions
Sham vibrating capsule, Vibrant Capsule (1 vibration), Vibrant Capsule (3 vibration), Vibrant Capsule (5 vibration)
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting Phase 1 Interventional Accepts healthy volunteers

The ENHANCE Study: taVNS and Psilocybin

NCT05866471
Conditions
Healthy, Psychedelic Experiences, Vagus Nerve Stimulation
Interventions
Psilocybin, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone, Sham taVNS
Drug · Device · Behavioral + 1 more
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Pain, Postoperative, Anterior Cruciate Ligament Injuries, Analgesics, Opioid
Interventions
IPACK, PLACEBO
Drug
Lead sponsor
Loyola University
Other
Eligibility
16 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Maywood, Illinois
Conditions
Mild Depression
Interventions
N-acetylcysteine, Mindfulness-based cognitive therapy, Placebo, Sham mindfulness-based intervention
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 24 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 3 Interventional Results available

Secondary Prevention of Venous Thrombo Embolism (VTE).

NCT00329238
Conditions
Thromboembolism
Interventions
Dabigatran, Warfarin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more
Completed Phase 1Phase 2 Interventional Results available

Use of Pyridostigmine for Constipation in Diabetics

NCT00276406
Conditions
Constipation, Diabetes Mellitus, Colonic Transit, Gastric Emptying
Interventions
Pyridostigmine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Constipation
Interventions
Vibrating Capsule, Sham capsule
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
22 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Canoga Park, California • Albuquerque, New Mexico • Willoughby, Ohio + 1 more
Completed Not applicable Interventional Results available

Feasibility of Placing Bravo PH Capsule in Proximal Esophagus

NCT00378898
Conditions
Gastroesophageal Reflux Disease
Interventions
BRAVO capsule, Fluoroscopy, sham BRAVO capsule placement
Device · Procedure · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression
Interventions
Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin, Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment
Drug · Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
22 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Austin, Texas
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Caffeine and Intermittent Hypoxia on Leg Function in Human Spinal Cord Injury

NCT02323698
Conditions
Spinal Cord Injuries
Interventions
Caffeine, AIH, Placebo, SHAM
Drug · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Knee Osteoarthritis, Primary Total Knee Arthroplasty, Physical Therapy, Pain, Knee Extension
Interventions
Ropivacaine, Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block, Saline
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Alport Syndrome
Interventions
Placebo Oral Capsule, Bardoxolone Methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 60 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more
Conditions
Diabetes Mellitus, Diabetic Macular Edema
Interventions
ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection
Drug · Other
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more